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Around half of the world’s population faces Helicobactor pylori (H. pylori) infection. Enormous progress has been made to understand the bacterial 
pathogenesis process and pathogen interaction with eukaryotic cells but infectious diseases are still the cause of premature death of humans 
around the world. H. pylori is categorized under class I carcinogen by the WHO based on clinical study results. This review paper discusses various 
attempts made to establish an efficient vaccine to manage H. pylori infection. Some of the problems in developing an efficient vaccine against H. 
pylori are recurrent or persistent infection, insufficient knowledge about the action specifically in case of probiotics, development of antibiotic 
resistance, and cost of therapy are noted. This research may come up with transient Nicotiana benthamiana with suitable H. pylori genes expressed 
as antigenic proteins, which can be used for further studies to develop a vaccine for gastric ulcer/cancer and generate good scientific data that can 
be helpful for scientists and researchers in this field. 
ABSTRACT 
This review article for monitors’ current approaches monitoring H. pylori infection since 1998 to 2019 using world-wide recognized journals and 
books, questioning its efficacies and whether these strategies help eradicate or there is a need to focus on several diversions. We provide scientific 
recommendations in eliminating H. pylori 
Keywords: Helicobacter pylori, 
through vaccination along with addressing the preventive vaccine for this pathogen rather than using 
defeated treatments with plant-based nil side effects solution. The information relies on the available content in Google Scholar and PubMed using 
the keywords listed below. 
Helicobacter pylori neutrophil-activating protein (HP-NAP), Cytotoxin-associated genes pathogenicity island 
(cag
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INTRODUCTION 
Apathogenic bacterium, H. pylori is a microaerophilic, gram-negative 
microorganism, was discovered in 1982 by Marshall and Warren in 
1984. H. pylorus has two original morphological shapes, bacillary 
and coccoidal. The virulent form being bacillary form, while the 
protective form is the coccoid form. The bacillary form projects 
many unipolar flagella. 
H. pylori 
A considerable amount of evidence suggests that bacterial genotype 
is an important factor determining the type of induced pathology. 
The nature and severity of a disease depends on both-host 
characteristics and environmental factors. Genetically modified 
Plant-based treatment is an interesting substitute to existing 
treatment methods, which could be target-specific as well as no or 
least side effects to humans against H. pylori. 
is persistent in an infected person’s stomach throughout a 
lifetime. It leads to chronic gastric inflammation that further causes 
diseases of the gastrointestinal tract like peptic ulcers, lymphoid tissue 
lymphoma, and gastric cancer. To avoid these ailments, this bacterial 
infection has to be eradicated and resistance to most of antimicrobial 
treatment calls for a new research in pharmaceutical science [1]. 
Virulence 
Helicobacter produces virulence factors that lead to the 
development of disease symptoms. The most extensively studied 
factors are adhesins that control adhesion of bacteria to gastric 
mucosal cells, urease-which neutralizes stomach’s acidic 
environment, CagA responsible for influencing host cell signal 
transduction pathways, VacA, a vacuolating toxin that regulates 
immune cell activity and NapA a protein that activates neutrophil. 
Urease plays a role in gastric acid neutralization and metabolization 
of urea into ammonia and CO2. Urease also exhibits strong 
immunogenic and chemotactic activity towards phagocytes, aids 
proinflammatory cytokines interleukin IL-6, (IL)-1β, IL-8, and 
tumoral necrosis factor-alpha (TNF-α) production. In the stomach, 
approximately 20% population of the H. pylori 
CagA, being the most destructive virulence factor, shows its 
presence along cag Pathogenicity Island (cagPAI), is known as the 
first bacterial oncoprotein. Its interaction with human proteins 
causes many irreversible changes to host tissues such as exponential 
rise in cell size, elevating motility, humming bird phenotype 
phenomena. Along with these, CagA destroys apical junctions 
altering the normal epithelial morphology. At every tyrosine 
phosphorylation site, termed EPIYA motif, CagA links to the cytosolic 
proteins in a phosphorylation-dependent fashion. Also, binding of 
CagA with host proteins in a phosphorylation-independent method 
triggers to adenocarcinoma in host cells. 
attach themselves to 
epithelial cells and the remaining is present in the mucosal layer [2]. 
The H. pylori 
VacA shows significant factors promoting the virulence of the 
protein (HP-NAP) triggers neutrophil activation aids in 
the essential process of bacterial growth by helping it in capturing. 
HP-NAP is significant in pathogenesisas it induces mononuclear and 
polymorphonuclear phagocyte adhesion and chemotaxis [3]. NADPH 
oxidase enzyme activates reactive oxygen species production (ROS) 
in the presence of HP-NAP [4]. HP-NAP additionally triggers the 
release of cytokines IL-23 and IL-12 by neutrophils and monocytes 
that have inflammatory effects [5]. Properties of HP-NAP facilitate 
increased inflammation of gastric mucosa and ROS persistently 
harming gastric cells. 
H. pylori 
strains with pathogenic properties. It forms pores in host cell 
membranes, promoting chlorine, pyruvate, bicarbonate ions, and urea 
to exit, which helped in its characterization [6]. VacA is generally a 
water-soluble protein residing on membranes to initiate the formation 
of a hexameric anion-selective pore. Reports of interference with the 
of in vitro antigen presentation process [7], apoptosis induction in 
epithelial cells [8] and inhibiting the process of in vitro T and B cell 
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activation and proliferation. One of the functions of VacA comprises of 
its initial activity of nutrient supplying for infection establishment. 
VacA facilitates infection persistence and chronicity by contributing to 
immune cell inhibition and cellular turnover balance alteration; it also 
leads to an increase in proliferation of cells and supports the 
establishment of many mutated cells, further contributing to the 
process of carcinogenesis.  
The cagA gene is on the cytotoxin-associated genes pathogenicity island 
(cagPAI), which induces severe inflammatory responses. The interaction 
of the immune system of the host with H. pylori 
Infection in childhood, H. pylori infection remains throughout life, despite 
of the host showing a spontaneously immune response by coating the 
invading pathogen with antibodies [9]. This bacterium develops 
processes to evade effective host immunity leading to longevity. 
leads to years of 
persistent infection and the chronic inflammation of gastric mucosa. 
 
 
Fig. 1: Model representing the role of H. pylori 
 
and other factors 
in gastric carcinogenesis 
Current status of H. pylori vaccine R and D activities 
Vaccine development for the eradication of H. Pylori infection has 
been extremely difficult [10]. Delivery systems and adjuvants can 
achieve a decent reduction in levels of colonization by H. pylori. 
Strategies for the production of suitable sterilizing immunity are yet 
to be worked upon. Mice which is immune after therapeutic 
vaccination is one of the first demonstrations for the efficacy of a 
therapeutic vaccine against bacterial pathogens. With a single 
exception, all attempts to convert this success from animal models 
towards clinical trials have turned out to be unsuccessful. Urease 
along with varied adjuvants, mechanism, delivery systems, served as 
the focus for most of the early clinical trials for H. pylori vaccine, 
generally showing no efficacy in humans. Novartis tried a unique 
approach by combining three H. pylori virulence factors (vacA, cagA, 
and NAP), which were then intramuscularly introduced with alum. 
This vaccine displayed immunogenic properties and was taken to 
the phase 1/2 trial but was not pursued further [11]. 
All vaccines for H. pylori currently are in very early stages of 
development (Phase 1/2 or preclinical). Purified and recombinant 
constituents of H. pylori antigens together with an adjuvant, 
constitute these vaccines.  
Preclinical 
EpiVax H. pylori vaccine is an epitope-based vaccine that has displayed 
therapeutic protection in mice [12]. It is an initiation vaccination along 
the DNA and peptide-liposome. Helicovaxor has two approaches, one 
with engineering a Vibrio cholera strain of vaccine having non-
pathogenic properties to express H. pylori antigens (HpaA, UreB and 
FlaA), and a strain of H. pylori which has been inactivated. Limited 
protection in BALB/c mice has been shown in two initial tests of 
epitope-based H. pylori antigen vaccines (Lp220) [11]. Probiotics are 
been identified as a delivery system for vaccines in recent years. When 
mice were administered oral dosage of Lactococcus lactis showing 
recombinant expression of cholera toxin B subunit and H. pylori urease 
epitopes, they showed some specific protection but this did not show 
improvement in the protection generally observed with standard 
recombinant antigen strategies [13]. Murdoch Children’s Research 
Institute (MCRI) is working to develop a vaccine that targets and 
inhibits inflammatory effects caused by this disease instead of 
targeting the eradication of H. pylori. 
In clinical trial 
Imevax, a vaccine that consists of H. pylori antigen gamma-glutamyl 
transpeptidase (GGT), a protein from the outer membrane and a 
mucosal adjuvant. IMX101 has completed phase I of the clinical trial. 
Previously developed vaccines have failed to provide complete 
protection because of the strategies of immune evasion shown by H. 
pylori [14]. GGT is one of the most important vaccine approaches that 
display significant potent immunosuppressive activity [11]. Therefore 
targeting and neutralizing of the defense mechanism of and allowing a 
more efficacious immune action to be generated rose against other 
antigenic vaccine components. This trial is attempting to develop an 
effective vaccine-mediated response by overcoming one mechanism of 
H. pylori evading host immunity. It is still to be established whether 
targeting one such mechanism is enough as these bacteria possess many 
such defensive strategies but it seems like a valid strategy to investigate. 
The trial has been completed, but results are yet to be available. 
  




Predicted role Associated with H. pylori-related diseases References 
BabA Binds to fucosylated-Leb babA2 allele has implicated in peptic ulcer disease and 
gastric cancer 
blood group antigen on 
cells 
[15, 16] 
SabA Binds to sialyl-Lexand sialyl-Lea None antigens and is 
involoved in activation of neutrophils 
[17] 
SabB Binding specificity is unknown Absence of SabB expression via phase variation is associated 
with duodenal ulcers 
[18] 
OipA OipA has been reported to assist in IL-8 
induction, but this association is not universal 
Expression of OipA is linked with cag status and development 
of duodenal ulcers ad gastric cancer 
[19] 
AlpA and AlpB Inactivation of these genes reduced adherence to 
gastric epithelial cells 
Unknown [20] 
Hp-NAP Activates neutrophils and promotes adhesion to 





Unknown Presence of plasticity region is accociated with development 
region of gastric cancer, MALT lymphoma, duodenal ulcers 
[22] 
IceA This encodes CATG-recognizing restriction 
endonuclease 
IceA1 associated with peptic ulcers, but is not universal  [23] 
DupA This encodes VirB4 ATPase homolog It is associated with duodenal ulcers but also reduces risk of 
gastric atrophy and cancer 
[24] 
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Classical whole-cell inactivated vaccines 
Vaccines constitute the most economical tool for prophylaxis of 
infectious diseases. In case of individual patients, H. pylori 
vaccination is more effective than antibiotic therapy decreasing the 
infection at population level leading to the eradication of the 
pathogen. Three main categories form active vaccines: killed 
vaccines, attenuated vaccines and subunit vaccines. Infected and 
non-infected volunteers were subjected to oral administration of H. 
pylori cells killed by formalin along with a mucosal adjuvant-a 
mutated form of heat liable E. coli toxin which is known to stimulate 
Th1 and Th2 immune responses [25]. Specific antigen secreting cell 
production was induced by the vaccine but it was not able to 
eradicate pre-existing infection. 
Subunit helicobacter vaccines-antigen selection 
It was found that only a small part of only 10 out of 400 examined H. 
pylori, antigens revealed protection in preclinical experiments [28]. 
The most promising candidates to construct an efficient vaccine might 
be abundant, surface-located, conserved, and seroreactive antigens. 
Conventional methodologies were used to select a few H. pylori 
antigens (CagA, VacA, HspA, NapA, catalase and urease sub-unit A and 
B) to evaluate their protective potential. None of these antigens fully 
protected humans despite showing immunogenic properties and 
protective properties in animal models (mice or gerbils) [29]. CagA 
and VacA, present in several prototypes of vaccines, have high 
polymorphic properties and are not conserved. Certain clinical isolates 
lack fully or partially the part of pathogenicity island formed by CagA 
gene. All genomes contain vacA gene expressed at different levels. 
CagA and VacA expressed by type I H. pylori strains, cause the most 
dangerous pathogenic effects. The majority of candidates for subunit 
vaccines that are analyzed consist of one or two antigens, but recent 
studies show that the efficacy of a vaccine can be increased by 
including more antigens. Clinical isolates of H. pylori show vast genetic 
diversity in recent studies. Thus, it is important to study the protein 
level comparison of different strains. 
Traditional methods used for identifying vaccine candidates are 
selected based on analyzing known pathogen virulence factors with 
concerning their immunogenicity. Methods of genetic engineering 
were developed, allowing genomic libraries to be constructed and 
screening them with specific antibodies obtained from patients and 
immunized animals. Recent progress in bacterial genome 
sequencing has reinforced the current approaches in identifying 
new, potential subunit vaccines. Genome sequencing of two H. pylori 
strains-26695 and J 99-have been done [26]. In silico analysis and 
genome comparison of various H. pylori isolates by microarray 
shows that their genomes contain 1111-1281 common genes [27]. 
Few out of these are considered for developing a vaccine. Assessing 
bacterial genome diversity, analyzing gene sets expressed in vivo, 
pathogen antigen screening and further assessing their uses in 
vaccine development. 
Immunoproteomics is a novel strategy combining standard 
proteomics with immunological screening and is currently the 
method of choice for identifying new antigens of diagnostic and 
protective values. It is proposed that highly specific antigens could 
be used as biomarkers of different pathologies induced by H. pylori 
infections, whereas novel, highly immunogenic, conserved, abundant 
and surface-located proteins could facilitate construction of an 
efficient anti-Helicobacter vaccine. Although proteomics is 
considered useful in evaluating the total protein content in bacterial 
cells and in studying protein-protein interactions, they display some 
significant limitations. One of the major problems is the fact that 
low-abundant and hydrophobic membrane proteins are 
undetectable by standard methods [30]. 
Bacterial cells (attenuated pathogenic bacteria and lactic acid 
bacteria) and viruses as carriers for H. pylori antigens 
Most pathogenic microorganisms are either restricted to mucosal 
membranes or need to cross them to achieve their proper infectious 
niche [31]. For years it was considered that due to the apparent 
compartmentalization of the mucosal and systemic immune systems, 
vaccines administrated parenterally are less effective in protection 
against mucosal pathogens than mucosal immunization. However, 
more recent data indicate that the protective mechanism can be also 
stimulated parenterally. The effect seems to be dependent on the 
antigen delivery system and type of adjuvant used for immunization. 
Moreover, it should be noticed that although H. pylori colonizes gastric 
mucosa, vaccine prototypes administrated parenterally were also 
evaluated [10, 32]. Delivery of vaccine antigens via the mucosal route 
can be carried out using different strategies. The best-examined 
strategy used both attenuated and commensal microorganisms as 
bacterial carriers [33]. Delivery of vaccine antigens by live bacterial 
cells has resulted in the elucidation of both mucosal and systematic 
immune responses. Several attenuated Salmonella strains have been 
exploited as delivery systems for H. pylori antigens, mainly for urease 
sub-units A and B [34]. The antigens were expressed either as 
cytoplasmic-or surface-located proteins. Rhiozo et al. showed that 
exposure of UreA on the surface of Salmonella cells by employing part 
of the E. coli adhesion AIDA-1 greatly reduced the level of H. pylori 
colonization compared to cytoplasm-located UreA [35]. Recently 
Smythies documented that the genetically engineered poliovirus can 
be employed as a carrier of H. pylori antigens (UreB) [36]. Vaccination 
of mice with a replicon construct resulted in the clearance of 
established H. pylori infection in 73% of animals compared to 31% of 
mice immunized with the vector alone. A few attempts have been also 
undertaken to evaluate lactic acid bacteria potential as carriers for H. 
pylori antigens [37, 38]. 
DNA Vs. antigen vaccination 
One of the two main deterrants to develop an effective vaccine for H. 
pylori is its unique characteristics and the other is the persistence of 
its infection. Antibiotic therapy and vaccination are the two major 
approaches to defeat the microorganism. Several attempts have 
been undertaken to estimate the strategy potential of developing a 
vaccine against H. pylori. Plasmid DNA containing urease, catalase or 
heat-shock protein-encoding genes as well as genes encoding 
immunogenic protein derived from H. pylori genomic library was 
administered to mice by different routes (intramuscularly, 
subcutaneously or intranasally) [34, 39].  
In some experiments, a decrease in the bacterial load in the stomach 
and induction of the humoral immune response was noticed. 
Hatzifoti, et al., also suggested that vaccination also results in an up-
regulation of the IL-10 level, whereas the detection of $-defensin in 
the stomach indicated that immunization modulates both innate and 
adaptive immune responses [30]. Attempts to employ attenuated 
Salmonella strains for anti-Helicobacter DNA vaccination have also 
been undertaken. Salmonella is an enteroinvasive pathogen which 
can target plasmid DNA, carrying heterologous genes cloned under 
the control of eukaryotic promoters, to antigen-presenting cells 
(APC), specifically to dendritic cells (DC) the major target cells 
processing the antigen. Expression of foreign antigens results in 
antigen presentation by class I MHC and stimulation of both Th1 and 
Th2, T lymphocytes [41, 42]. Salmonella expressing H. pylori hpaA 
and napA genes cloned into eukaryotic expression vectors showed 
high immunogenicity when evaluated in the murine model. Hatzifoti 
et al., [40] using the urease B DNA vaccine pointed out the role of an 
innate immune response in reducing H. pylori colonization of the 
murine gastric mucosa. 
Attempts with probiotics 
Several probiotic therapies in H. pylori treatment leads to an 
improved tolerance by prevention of outdated treatment and their 
side effects. Researchers reveal the acceptance of different 
probiotics usage against H. pylori along with the detailed 
mechanism of probiotic action against H. pylori
Probiotics administration in 
, such as mucosal 
barrier efficacy, competition for adhesion, and immunomodulatory 
mechanisms [43, 44]. 
H. pylori-related diseases has shown 
consistent improvement of symptoms in patients. However, its 
efficacy is related considerably on factors such as H. pylori strain, the 
colonization size, density and the extent of inflammation. Studies 
reveal that extent of infection of this bacterium determines the risk 
of development of peptic ulcer disease and gastric cancer. Thus, 
medication of probiotics at the very beginning could bypass 
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permanent damage by H. Pylori 
 
related diseases [45]. The main 
issues with considering probiotics to manage H. pylori are 
insufficient knowledge of their action mechanism and inconsistent 
application findings [46]. 
 
Fig. 2: Schematic representation of the factors contributing in H. pylori 
 
infections [38] 
Recombinant protein expressions in plants 
With notable damage and development of resistance towards 
existing treatment, antibiotics along with triple therapy with 
clarithromycin is not the best option for H. pylori infection, 
especially in remote areas where the local resistance to this 
antibiotic is 20% or higher. Therefore, alternate treatments have 
been proposed for the eradication of H. pylori
Recombinant protein production on an industrial scale is in high 
demand due to their applications as diagnostic reagents, vaccines, and 
therapeutic agents. Heterologous proteins can be expressed in 
different systems through recombinant DNA technology. Earlier 
prokaryotic hosts were chosen due to their low overall cost and short 
production time scale. Protein classes that can be produced in 
prokaryotic systems are limited and post-translational modifications 
are not performed by them [47]. Therefore eukaryotic hosts: yeast, 
insects, and mammalian cell cultures and transgenic animals are 
focused upon. Some downsides of mammalian cell cultures and yeast, 
which are the main expression systems used, are cost, scalability 
potential, pathogenicity risk, and authenticity. Plants are a simple and 
inexpensive alternative to produce recombinant proteins at a scalable 
level allowing the development and production of safe and effective 
new vaccines and pharmaceutical compounds for populations that are 
in dire need of them. There are many advantages of recombinant 
proteins obtained from plants that are engineered genetically. 
Recombinant protein accumulation inside a plant cell in specific plant 
organs (E. G. in seeds) or in specific plant organelles (E. G. 
chloroplasts) occurs throughout the entire plant and is dependent 
upon the promoters used. Target for an accumulation of recombinant 
protein is seeds because of the high content of protein in seeds [48].  
.  
H. pylori genes showing pathogenic properties have been greatly 
studied to initiate a disirable treatment for its complete removal 
from the human system. Many researchers are working on 
virulent genes of H. pylori, vector systems to introduce in 
suitable plant cells to obtain genetically altered traits to aid the 
treatment of H. pylori. A total of 30 regenerated rice plants with 
hygromycin resistance were obtained when UreB (urease 
subunit of H. pylori) was introduced in rice plants via 
Agrobacterium-mediated transformation. This way, the 
expression of urease was curtailed consuming using transgenic 
rice, which could not neutralize the acidic medium in the 
stomach leading to bacterium death [49]. 
Another approach was laid by Zhang, et al., who initiated gene 
transformation of UreB in carrot through Agrobacterium-mediated 
transformation, got successful after the expressional traits of UreB 
proteins (25mug/g) in roots) could activate an immune response in 
mice. This result suggests that the UreB transgenic carrot could be a 
potential vaccine for H. pylori infection [50]. 
Using the tree Nicotiana benthamiana 
Several plants, such as Polygonum minus [51] and transient 
Nicotiana benthamiana have proved to be an aid for H. pylori 
treatment. Nicotiana benthamiana with cagA, vacA and NapA genes 
expressed as antigenic proteins can be used for further studies to 
develop a vaccine for gastric ulcer/cancer and other ailments caused 
by H. pylori. This tree has already added scientific appreciation 
towards its role in plant biology, therapeutic and tremendous 
biotechnology applications [52]. Recently, the rise of research on 
this tree is noted for its purpose as a useful tool in the study of plant 
microbiology and protein-protein interactions, pathogen-host 
interactions. Since it can easily exhibit foreign traits, it is considered 
as one of the best choices for plasmid-encoded virus interactions, 
screen for gene functions with virus-induced gene silencing (VIGS), 
and transiently express genes by leaf agroin filtration. 
  
Table 2: Genetically modified organisms to treat H. pylori 
Transgenic plant Virulent gene from H. pylori References 
Callus of Carrot UreB gene [52] 
Nicotiana benthamiana UreB gene [52] 
Nicotiana tobacum Heat shock protein A (HspA) [53] 
Arachis hypogaea L. (peanut) UreB [54] 
Arabidopsis Thaliana HP1341 (iron-dependent siderophore transporter protein) [55] 
Acacia nilotica and Calotropis procera, oregano 
and cranberry, Calophyllum brasiliense,  
Urease [56, 57] 
Paeonia lactiflora roots, UreB [58] 
 
One distinctive feature added with three notable technologies has 
strongly recommended the rise and popularity of N. benthamiana. 
These are its easy susceptibility to plant viruses, development viral 
vectors to study foreign genes expression, the development of virus 
vectors in silencing genes signals placed on the borders of a T-DNA 
plasmid, and are delivered into the leaf via Agrobacterium in filtration, 
and to develop visual reporter genes. 72 base-pair of N. benthamiana 
showcases an insertion in its RNA-dependent RNA polymerase gene 
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(Rdr1), which easily dysfunctions after it terminates the gene’s open 
reading frame. This makes it easily susceptible to a viral infection 
making it an excellent host for virus-delivered gene expression and 
gene silencing [59, 60]. So, significant interest has developed to utilize 
this plant to exhibit desired genes traits to obtain a suitable cure to 
nullify H. pylori virulence in humans.  
CONCLUSION 
FUNDING 
H. pylori have proved to be a significant public health risk pathogen 
and several attempts to completely eradicate this bacterium have 
not been achieved so far. Yet, no target-specific, complete removal of 
the infection is found. Plant-based novel approaches are been 
researched to aim for complete cure from pylori caused diseases. 
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